Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/60275
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
3100-12-31
Objetivos de Desenvolvimento Sustentável
03 Saúde e Bem-EstarColeções
Metadata
Mostrar registro completo
IMMUNOGENICITY, EFFECTIVENESS, AND SAFETY OF INACTIVATED VIRUS (CORONAVAC) VACCINE IN A TWO-DOSE PRIMARY PROTOCOL AND BNT162B2 HETEROLOGOUS BOOSTER IN BRAZIL (IMMUNITA-001): A ONE YEAR PERIOD FOLLOW UP PHASE 4 STUDY
COVID-19
vaccine
immune response
coronavac
BNT162b2
heterologous booster
Autor(es)
Grenfell, Rafaella Fortini Queiroz
Almeida, Nathalie Bonatti Franco
Filgueiras, Priscilla Soares
Corsini, Camila Amormino
Gomes, Sarah Vieira Contin
Miranda, Daniel Alvim Pena de
Lourenço, Adelina J.
Martins Filho, Olindo Assis
Oliveira, Jaquelline Germano de
Carvalho, Andrea Teixeira
Campos, Guilherme RF
Nogueira, Maurício Lacerda
Alves, Pedro Augusto
Fernandes, Gabriel da Rocha
Castilho, Leda dos Reis
Lima, Túlio Macedo
Abreu, Daniel Paiva Barros de
Alvim, Renata Guimaraes Ferreira
Silva, Thais Barbara de Souza
Jeremias, Wander de Jesus
Otta, Dayane Andriotti
Azevedo, Ana Caroline Campi
Almeida, Nathalie Bonatti Franco
Filgueiras, Priscilla Soares
Corsini, Camila Amormino
Gomes, Sarah Vieira Contin
Miranda, Daniel Alvim Pena de
Lourenço, Adelina J.
Martins Filho, Olindo Assis
Oliveira, Jaquelline Germano de
Carvalho, Andrea Teixeira
Campos, Guilherme RF
Nogueira, Maurício Lacerda
Alves, Pedro Augusto
Fernandes, Gabriel da Rocha
Castilho, Leda dos Reis
Lima, Túlio Macedo
Abreu, Daniel Paiva Barros de
Alvim, Renata Guimaraes Ferreira
Silva, Thais Barbara de Souza
Jeremias, Wander de Jesus
Otta, Dayane Andriotti
Azevedo, Ana Caroline Campi
Afiliação
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Infectious Diseases. College of Veterinary Medicine. University of Georgia. Athens, GA, United States
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Infectious Diseases. College of Veterinary Medicine. University of Georgia. Athens, GA, United States
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Hospital da Baleia. Benjamin Guimarães Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de Imunologia Celular e Molecular. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil
Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil/Hospital de Base. São José do Rio Preto, SP, Brazil/Department of Pathology, University of Texas Medical Branch. Galveston, TX, United States
Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Biosystems Informatics. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de farmacologia experimental. Faculdade de Farmácia. Universidade Federal de Ouro Preto. Ouro Preto, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Infectious Diseases. College of Veterinary Medicine. University of Georgia. Athens, GA, United States
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Hospital da Baleia. Benjamin Guimarães Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de Imunologia Celular e Molecular. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil
Laboratorio de Pesquisas em Virologia. Faculdade de Medicina de São Jose do Rio Preto. São Jose do Rio Preto, SP, Brazil/Hospital de Base. São José do Rio Preto, SP, Brazil/Department of Pathology, University of Texas Medical Branch. Galveston, TX, United States
Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Biosystems Informatics. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Cell Culture Engineering Laboratory. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brazil
Imunologia de Doenças Virais. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Laboratorio de farmacologia experimental. Faculdade de Farmácia. Universidade Federal de Ouro Preto. Ouro Preto, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Grupo Integrado de Pesquisa em Biomarcadores. Rene Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil
Resumo em Inglês
Background: Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.
Methods: We bring pioneering contributions on the maintenance of the immune response over a year on a real-life basis study in individuals who underwent vaccination with two doses of CoronaVac and BNT162b2 booster after 6-months of primary protocol.
Findings: Elevated levels of anti-spike IgG antibodies were detected after CoronaVac vaccination, which significantly decreased after 80 days and remained stable until the introduction of the booster dose. Heterologous booster restored antibody titers up to-1·7-fold, changing overall seropositivity to 96%. Titers of neutralising antibodies to the Omicron variant were lower in all timepoints than those against Delta variant. Individuals presenting neutralising antibodies against Omicron also presented the highest titers against Delta and anti-Spike IgG. Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. A stronger interaction between those mediators was noted over time. Prior exposure to the virus leaded to a more robust cellular immune response and a rise in antibody levels 60 days post CoronaVac than in individuals with no previous COVID-19. Both vaccines were safe and well tolerated among individuals.
Interpretation: Our data approach the effectiveness of CoronaVac association with BNT162b2 from the clinical and biological perspectives, aspects that have important implications for informing decisions about vaccine boosters.
Palavras-chave em inglês
SARS-CoV-2COVID-19
vaccine
immune response
coronavac
BNT162b2
heterologous booster
Compartilhar